Cosmetic / skin
Melanotan II
MT-II · MT2
High consumer recognition for tanning and libido, amplified by a wave of 'nasal tanning' social-media content. Distinct from FDA-approved afamelanotide (Scenesse).
Evidence
Bhuman trials
Status
Banned / prohibitedas of 2026-06
Approval
Not approved
Category
Cosmetic / skin
Route
Subcutaneous · Intranasal
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
Loading ~100-250 mcg/day, then ~500-1000 mcg 1-2x/week maintenance SC
Titration
Start low to gauge nausea/BP
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5 mg/mL; 500 mcg = 10 U on U-100. Intranasal absorption is unpredictable - mcg figures don't translate.
Reconstitution calculatorlive tool
10units
on a U-100 syringedraw to the 10 mark
Concentration5 mg/mL
Draw volume0.1 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. Banned as a medicine in the UK; Schedule 9 (prohibited) in Australia (Feb 2026).
Status
Banned / prohibited
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 ~22 Apr 2026; on the ~Feb 2027 PCAC
PCAC review
~2027-02
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows
Early-phase human + small tanning studies; NO approval. Evidence is largely evidence of HARM (case reports).
04Safety
Contraindications
- Melanoma / dysplastic nevi / skin-cancer historyhard stop
- Uncontrolled hypertension / known CVDhard stop
- History of priapism / sickle cell
- Pregnancyhard stop
Key interactions
- PDE5 inhibitors (HARD_STOP/avoid; severe hypotension/syncope + priapism)
Serious signals
- Priapism (urologic emergency)
- PRES; rhabdomyolysis; renal infarction (case reports)
- Mole darkening / new nevi / melanoma - complicates surveillance
Monitoring
Regular dermatologic mole surveillance; baseline BP.
05Related in Cosmetic / skin
06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
RegulatoryTGA Schedule 9 2026Regulatory action · TGA schedulingPeer-reviewedcase reportsEvidence — peer-reviewed studyHow we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium